FDA Investigator Martin K Yau, PhD

Martin K Yau, PhD has conducted inspections on 27 sites in 4 countries as of 06 Dec 2010. See below for a list of the FDA enforcement documents resulting from those inspections.

Investigator Details

Number of Inspected Sites:
27
Last Inspection Date:
06 Dec 2010
Investigator Role:
FDA Investigation Participant
Redica ID:
100007102
Countries of Inspections:
Canada, United States of America, United Kingdom of Great Britain and Northern Ireland, Germany
FDA Investigators that have inspected at least one site in common with Martin K Yau, PhD:
Alan E Mehl, Alan P Kurtzberg, Albert F Peacock, PhD, Alicia M Mozzachio, Allen F Hall, Andrea A Branche, Andrea D Swingle, Andrew B Bevill, Angel S Johnson, Arindam Dasgupta, PhD, Barbara A Rusin, Barbara Janine Breithaupt, Barbara M Frazier, Bonita S Chester, Brandon L Mariner, Brittany D Terhar, Brooke K Higgins, Bruce H Mccullough, Brunilda Torres, Byungja E Marciante, Candice C Mandera, Candice J Cortes, Carl J Montgomery, Carla A Norris, Carol Rivera Lopez, PhD, Carol S Sanchez, CDR Kimberly Y Martin, Charles M Edwards, Charles R Bonapace, PhD, Charles R Cote, RIC, Chase Bourke, PhD, Chengru Zhu, Chilton L Ng, Chris A Sack, Christine M Whitby, CSO, Cordelia J Brammer, Corey K Reno, Craig A Garmendia, Cynthia A Harris, MD, RN, Dana M Klimavicz, Danial S Hutchison, Daniel R Hurt, David Perkins, Dawn C Olenjack, Dawn L Wydner, Debra I Love, Denise L Burosh, Denise M Visco, Investigator, Deniza Karacic, Diane Cvan Leeuwen, Dianne H Milazzo, Dina A Tallman, Douglas A Campbell, Dr. Abhijit Raha, PhD, Dr. Gopa Biswas, PhD, Dr. Mark J Seaton, PhD, Dr. Sriram Subramaniam, PhD, Dr. Zhou Chen (nmi), MD PhD, Edwin Martinez, Elise A Murphy, Elizabeth D Connell, Eric S Weilage, Erin L Mcfiren, Evelyne L Weaver, Farhana Khan, Frederic W French, III, Gajendiran Mahadevan, PhD, George C Amedro, Gerald N Mcgirl, DDS, Gifford Whitehurst, Jr, Gregory W Smith, Gretchen Lf Trendel, Gwyn G Dickinson, Hugh M Mcclure, II, Huixia Zhang, Hyojong Kwon, PhD, Ingrid Y Johnson, Iris C Macinnes, Jacqueline A O'shaughnessy, PhD, James M Kewley, James P Stumpff, Jane E Nelson, Jasjeet K Sekhon, Jean M Kelahan, Jeanne D Shaffer, Jeffrey P Raimondi, Jeffrey W Shrifter, DPM, Jennifer A Longie Vollom, Jennifer L Sheehan, Jill J Tillman, Joanne M Schlossin, Jodi M Gatica, Joel D Martinez, John A Kadavil, PhD, Jonee J Mearns, Julie N Vosilus, Jyoti B Patel, PhD, Kara A Scheibner, PhD, Karen C Daugherty, Karen M Cooper, Karen M Kondas, Kathleen B Swat, Kellia N Hicks, Larry K Austin, Laura E Garcia, Lawrence Y Lee, PhD, LCDR Matthew R Mcnew, MPH, REHS/RS, Leighton Kn Gai, Li Hongpaul Yeh, PhD, Lillie M Young, Linda R Kuchenthal, Linda Thai, Lisa B Orr, Lisa Hayka, Lisa P Oakes, Lynette P Salisbury, Maira P Brading, Margaret M Annes, Margaret M Sands, Matthew R Sleeter, Melissa J Garcia, Melkamu Getie Kebtie, PhD, Merelynn Rhoten, Michael F Skelly, PhD, Michael P Sheehan, Michael S Smoker, Michael Serrano, Michele L Obert, Mohsen Rajabi Abhari, FDA, Monique M Brooks, Muralidhara B Gavini, PhD, Nancy A Bellamy, Nathaniel R Esaw, Neal L Adams, Nerizza B Dalena, Nerizza B Guerin, Nicholas F Lyons, Nicola M Fenty Stewart, Nikisha M Bolden, Nilufer M Tampal, PhD, Nina Yang, Patrick D Stone, MS, Paula J Perry, Paula M Laplant, Perry H Gambrell, Raymond T Oji, Rebecca Rodriguez, Rita K Kabaso, Robert Barron, Robert C Steyert, Robert D Tollefsen, Robert T Lorenz, Ronald R Ruff, Ronda Rloyd Jones, Roy R Rinc, Sam H Haidar, PhD, Samantha J Pinizzotto, D V M, Samuel H Chan, PharmD, Sandra A Hughes, Sarah Forney, Scott B Laufenberg, Sean W Linder, Sean Y Kassim, PhD, Seongeun Cho (Julia), PhD, Sherry L Secrist, BLT DO, Shirley H Isbill, Shirley J Berryman, Shwnji Susie Lee, Srinivas R Chennamaneni, PhD, Sripal R Mada, PhD, Stephanie L Shapley, Stephanie Mangigian, MS/OSH, RN, Steven Eastham, Susan D Yuscius, Susan F Laska, MS, Susie H Lee, Tamal K Chakraborti, PhD, Tara L Greene, Terrance L Thomas, Truong Xuan Nguyen (Andy), Victoria A Wagoner, Vinh T Phan, Wayne D Mcgrath, William H Linkroum, William L Bargo, Xiaohan Cai, PhD, Xikui Chen (nmi), PhD, Yih Chain Huang, PhD, Zachary A Bogorad

Martin K Yau, PhD's Documents

Publish Date Document Type Title
June, 2002 FDA 483 GlaxoSmithKline - Form 483, 2002-06-21
June, 2004 EIR Syneos Health Clinical, Inc. - EIR, 2004-06-25
May, 2000 EIR NUVISAN GmbH - EIR, 2000-12-06
June, 2002 FDA 483 A. J. Stewart, B.Sc., MRCGP - Form 483, 2002-06-12
October, 2002 FDA 483 Bioanalytical Systems Inc - Form 483, 2002-10-30
September, 2000 FDA 483 Quest Diagnostics - Form 483, 2000-09-14
November, 2002 FDA 483 Response Gaetano Morelli, M.D. - Form 483R, 2002-12-02
December, 2010 FDA 483 Cetero Research - Form 483, 2010-12-10
June, 2000 EIR Worldwide Clinical Trials Early Phase Servcies/Bioanalytical Sciences, Inc. - EIR, 2000-06-30
November, 2002 EIR Gary Burrs, M.D. - EIR, 2005-03-25
May, 2004 FDA 483 Abbott Laboratories - Form 483, 2004-05-28
November, 2002 FDA 483 Response Gary Burrs, M.D. - Form 483R, 2002-12-02
May, 2007 FDA 483 Biovail Contract Research - Form 483, 2007-05-10
June, 2000 FDA 483 Worldwide Clinical Trials Early Phase Servcies/Bioanalytical Sciences, Inc. - Form 483, 2000-06-30
November, 2002 EIR Gaetano Morelli, M.D. - EIR, 2005-03-25
November, 2002 FDA 483 Gaetano Morelli, M.D. - Form 483, 2002-11-15
October, 2002 FDA 483 Response Bioanalytical Systems Inc - Form 483R, 2002-11-08
July, 2001 FDA 483 PPD Development, L.P. - Form 483, 2001-07-26
May, 2000 FDA 483 NUVISAN GmbH - Form 483, 2000-05-12
July, 2006 EIR Catalent CTS, LLC - EIR, 2006-07-20
July, 2001 EIR PPD Development, L.P. - EIR, 2001-07-26
May, 2002 EIR PPD Development, L.P. - EIR, 2002-05-17
October, 2004 FDA 483 MDS Pharma Services - Form 483, 2004-09-21
December, 2001 FDA 483 Labcorp Early Development Laboratories, Inc. - Form 483, 2001-12-06
January, 2004 EIR NUVISAN GmbH - EIR, 2004-06-02
January, 2000 FDA 483 Arkansas Childrens Hospital Blood Bank/HT - Form 483, 2000-01-27
September, 2000 FDA 483 Response Quest Diagnostics - Form 483R, 2001-02-15
July, 2003 FDA 483 Response MDS Pharma Services - Form 483R, 2003-07-17
June, 2004 FDA 483 Syneos Health Clinical, Inc. - Form 483, 2004-06-25
July, 2003 FDA 483 MDS Pharma Services - Form 483, 2003-07-17
March, 2003 EIR AAI Pharma Services - EIR, 2003-03-11
June, 2000 FDA 483 MDS Harris - Form 483, 2000-06-23
January, 2000 EIR Henry C Farrar, MD - EIR, 2000-01-27
November, 2002 FDA 483 Neopharm Labs Inc - Form 483, 2002-11-15
December, 2001 EIR Labcorp Early Development Laboratories, Inc. - EIR, 2001-12-06
June, 2004 FDA 483 Response Syneos Health Clinical, Inc. - Form 483R, 2004-07-13
October, 2004 EIR MDS Pharma Services - EIR, 2007-06-15
November, 2002 EIR Neopharm Labs Inc - EIR, 2003-01-07
December, 2001 FDA 483 Response Labcorp Early Development Laboratories, Inc. - Form 483R, 2001-12-20
November, 2002 FDA 483 Gaetano Morelli, M.D. - Form 483, 2002-11-15
May, 2002 FDA 483 PPD Development, L.P. - Form 483, 2002-05-17
September, 2000 EIR Quest Diagnostics - EIR, 2001-01-11
August, 2003 FDA 483 Mylan Pharmaceuticals Inc. - Form 483, 2003-08-01
October, 2002 EIR Bioanalytical Systems Inc - EIR, 2002-10-30
January, 2002 FDA 483 Syneos Health Clinique Inc - Form 483, 2002-01-21
July, 2003 EIR MDS Pharma Services - EIR, 2003-09-24
April, 2008 FDA 483 COVANCE BIOANALYTICAL SERVICES, LLC - Form 483, 2008-04-25

Experience Redica Systems’ NEW investigator profiles and dashboards

Redica Systems customers get access to over 1,400 FDA Investigator profiles, containing powerful analysis like:

  • Total inspections conducted
  • 483 rate
  • OAI rate
  • Warning Letter rate
  • Inspections by Industry, Scope, and Inspection Reason
  • And much more

Investigator Profiles are not sold as on-demand documents. If you’d like to see one, fill out the form below to connect with our Sales Team and get it in your inbox as little as 24 hours.

FDA Investigator Profile Icon

Talk to sales to access our investigator profiles

Loading...

Investigator Profiles Are Just the Tip of the Iceberg

Becoming a Redica Systems customer not only provides you with unlimited access to profiles similar to the one above for every current and former FDA Investigator, but also grants you access to:

Inspection Intelligence

  • Pre-Approval Inspection (PAI) trends
  • The ability to filter nearly any FDA enforcement action by GxP labels like GMP, GCP, etc.
  • Latest 483s: see what the trends are across all FDA Investigators
  • CFR Heatmap: Citations aggregated by Subpart by Year

Vendor Intelligence

  • Full inspection histories for your vendors down to the specific site level
  • All of the functionality mentioned above but isolated to just your vendors

Regulatory Intelligence

  • Zero in on the trends for a specific agency/regulator (ex. FDA, MHRA, EMA, Health Canada)
  • All the latest "Signals" from agencies around the world, segmented by Country, Type (ex. Guidance, Decree...), Category (ex. Rules/Regulations/Guidance, News, Reports...), Theme (ex. Cell and Gene Therapy, AI...), and more